 |
|
|
|
|
Product Details:
Payment & Shipping Terms:
|
| Product Name: | Sildenafi | Other Name: | Revatio,Viagraa |
|---|---|---|---|
| CAS: | 139755-83-2 | Appearance: | White Powder |
| Usage: | Treating ED | Storage: | Cool And Dry |
| Sample Order: | 1.0 Kilogram | Delivery: | 100% Guaranteed |
| High Light: | Sildenafil Viagra Erectile Dysfunction Medication,White Erectile Dysfunction Medication,Cas 139755-83-2 |
||
Pharmaceutical Raw Materials Sildenafile Viagraa Erectile Dysfunction Medication Powder Cas 139755-83-2
Pharmacologic action:
Sildenafi is a selective inhibitor of cyclic guanosine phosphate (cGMP) specific type 5 phosphodiesterase (PDE5), and is an oral drug for the treatment of ED. The physiological mechanism of normal penile erection involves the release of nitric oxide (NO) during sex stimulation Nitric oxide activates the guanosine cyclase in the smooth muscle cells of the penile cavernose, leading to an increase in the level of cGMP, which makes the smooth muscle in the sponge relax, the cavernous sinus dilates, and the blood inflow of the peniss erectile dysfunction is mainly due to the smooth muscle relaxation disorder of the penile cavernose Sildenafi has no direct relaxation effect on the isolated human spongiform, but can enhance the effect of nitric oxide by inhibiting the decomposition of PDE5 to cGMP in the spongiform.
Product Description:
| Product name | Sildenafi |
| Other names: | Revatio,Viagraa |
| CAS NO. | 139755-83-2 |
|
Appearance |
White powder |
| C22H30N6O4S | |
| Boiling point | 672.4ºC at 760 mmHg |
| Melting point | 187-189°C |
|
Flashing point |
360.5ºC |
| Grade | Pharmaceutical grade |
When local nitric oxide release is caused by sex stimulation, sildenafl inhibits PDE5, which can increase the level of cGMP in the spongiform, relax the smooth muscle of the spongiform, and blood flows into the spongiform Studies have shown that erectile response increases with the increase of dose and plasma concentration. The efficacy of sildenafl can last for 4h(but is weaker than 2h). In vitro experiments have shown that sildenafi has high selectivity for PDE5, which is more than 80 times of PDE1 and 700 times of PDE4 and 4000 times of PDE3 Since PDE3 is related to the control of myocardial contractility, there is no PDE5 in the myocardium, so sildenafl has no positive inotropic effect and does not directly affect myocardial contractility However, sildenaf can cause systemic circulation vasodilation, and high dose (100mg) oral administration can lead to a decrease in supine blood pressure [average maximum reduction of 1.12/0.73kPa(8.4/5.5mmHg)], and the most significant decrease in blood pressure 1~2 hours after taking sildenafl.
Therefore, sex activity may induce cardiac events at peak blood concentration The selective effect of sildenafl on PDE5 is only 10 times that on PDE6, an enzyme present in the retina. Therefore, sildenafl may cause abnormal color vision at high doses or at high blood concentrations. In addition to the smooth muscle of human spongy body, low concentrations of PDE5 have also been found in platelets, blood vessels, visceral smooth muscle and skeletal muscle Sildenafei may enhance antiplatelet aggregation (in vitro) by inhibiting PDE5 in these tissues, inhibiting platelet thrombosis (in vivo) and peripheral vasodilation (in vivo).
Product Photos:
Certifications:
FAQ:
Contact Person: Jennifer
Tel: +8615686296679
